Eupraxia Pharmaceuticals
EPRX
9 hedge funds and large institutions have $5.63M invested in Eupraxia Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
24% more capital invested
Capital invested by funds: $4.55M → $5.63M (+$1.09M)
13% more funds holding
Funds holding: 8 → 9 (+1)
0.08% more ownership
Funds ownership: 5.05% → 5.13% (+0.08%)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$35.1K |
| 2 |
Millennium Management
New York
|
+$29.6K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$22.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$14.8K |
| 2 |
SC
Scotia Capital
Toronto,
Ontario, Canada
|
-$13.5K |
| 3 |
1WA
180 Wealth Advisors
Federal Way,
Washington
|
-$7.4K |
| 4 |
TWC
TD Waterhouse Canada
Toronto,
Ontario, Canada
|
-$3.83K |
| 5 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$317 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SC
1
Scotia Capital
Toronto,
Ontario, Canada
| $4.26M | -$13.5K | -4,562 | -0.3% |
|
|
2
Royal Bank of Canada
Toronto,
Ontario, Canada
| $898K | +$35.1K | +11,858 | +4% |
|
|
3
Bank of Montreal
Toronto,
Ontario, Canada
| $178K | +$22.2K | +7,500 | +15% |
|
4
Goldman Sachs
New York
| $109K | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| $88.8K | -$14.8K | -5,000 | -15% |
|
6
Raymond James Financial
St Petersburg,
Florida
| $36.8K | +$34.4K | +11,613 | New |
|
|
1WA
7
180 Wealth Advisors
Federal Way,
Washington
| $33.3K | -$7.4K | -2,500 | -19% |
|
|
8
Millennium Management
New York
| $31.3K | +$29.6K | +10,000 | New |
|
|
9
National Bank of Canada
Montreal,
Quebec, Canada
| $135 | -$317 | -107 | -71% |
|
|
TWC
10
TD Waterhouse Canada
Toronto,
Ontario, Canada
| – | -$3.83K | -1,500 | Closed |
|
EPRX Hedge Fund Activity: Q4 2024 in Review
9 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Eupraxia Pharmaceuticals (EPRX) for Q4 2024, worth a combined $5.63M — up 24% from $4.55M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new EPRX positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 4 trimmed.
The largest buyer was Royal Bank of Canada, adding an estimated $35.1K. The largest seller was UBS Group, cutting an estimated $14.8K.
- 9 institutional investors held Eupraxia Pharmaceuticals (EPRX) as of Q4 2024, up from 8 in Q3 2024.
- Funds reported $5.63M of Eupraxia Pharmaceuticals stock for Q4 2024, up 24% quarter-over-quarter.
- 2 funds opened new Eupraxia Pharmaceuticals positions in Q4 2024 and 1 closed out, a net change of +1 holder.
- The largest Eupraxia Pharmaceuticals buyer in Q4 2024 was Royal Bank of Canada, an estimated $35.1K added.
- The largest Eupraxia Pharmaceuticals seller in Q4 2024 was UBS Group, an estimated $14.8K sold.
Based on aggregated 13F filings for Q4 2024.